Anticorps CD47 (BRIC 126) | SCBT - Santa Cruz Biotechnology
Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma | Haematologica
2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis | Arteriosclerosis, Thrombosis, and Vascular Biology
Cells | Free Full-Text | Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
Targeting the CD47/SIRPɑ Axis in Cancer Immunotherapy
CD47 - an overview | ScienceDirect Topics
Role of CD47 in Hematological Malignancies | Journal of Hematology & Oncology | Full Text
The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions | bioRxiv
Human lung adenocarcinoma CD47 is upregulated by interferon-γ and promotes tumor metastasis: Molecular Therapy - Oncolytics
CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes | American Journal of Physiology-Cell Physiology
CD47 — Wikipédia
Vaccines | Free Full-Text | Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
CD47-related Signaling Pathways & Research Progress on the Relationship with Related Diseases (Part Two) – Creative Biolabs Blog